Edward Chow

Kyan Technologies Pte Ltd. is a Delaware corporation that uses AI-based technology to redefine each stage of drug development, from lead optimization through clinical trials. Kyan's flagship platform, optim.ai, employs efficient experiments and relevant, real-time data to power its optimization core. The platform has been validated in more than 40 indications/conditions and has been applied clinically for dosage optimization in solid cancer and HIV. Kyan also works with industry partners to optimize their assets and products. The Singaporean company's mission is to bridge the cancer care gap by advancing revolutionary technologies. The company was founded by Dean Ho, Chih-Ming Ho, and Edward Chow. Hugo Saavedra has been the CEO of the company since 2021.

Kyan Technologies Pte Ltd. is a Delaware corporation that uses AI-based technology to redefine each stage of drug development, from lead optimization through clinical trials. Kyan's flagship platform, optim.ai, employs efficient experiments and relevant, real-time data to power its optimization core. The platform has been validated in more than 40 indications/conditions and has been applied clinically for dosage optimization in solid cancer and HIV. Kyan also works with industry partners to optimize their assets and products. The Singaporean company's mission is to bridge the cancer care gap by advancing revolutionary technologies. The company was founded by Dean Ho, Chih-Ming Ho, and Edward Chow. Hugo Saavedra has been the CEO of the company since 2021.

Kyan Technologies Pte Ltd. is a Delaware corporation that uses AI-based technology to redefine each stage of drug development, from lead optimization through clinical trials. Kyan's flagship platform, optim.ai, employs efficient experiments and relevant, real-time data to power its optimization core. The platform has been validated in more than 40 indications/conditions and has been applied clinically for dosage optimization in solid cancer and HIV. Kyan also works with industry partners to optimize their assets and products. The Singaporean company's mission is to bridge the cancer care gap by advancing revolutionary technologies. The company was founded by Dean Ho, Chih-Ming Ho, and Edward Chow. Hugo Saavedra has been the CEO of the company since 2021.

Kyan Technologies Pte Ltd. is a Delaware corporation that uses AI-based technology to redefine each stage of drug development, from lead optimization through clinical trials. Kyan's flagship platform, optim.ai, employs efficient experiments and relevant, real-time data to power its optimization core. The platform has been validated in more than 40 indications/conditions and has been applied clinically for dosage optimization in solid cancer and HIV. Kyan also works with industry partners to optimize their assets and products. The Singaporean company's mission is to bridge the cancer care gap by advancing revolutionary technologies. The company was founded by Dean Ho, Chih-Ming Ho, and Edward Chow. Hugo Saavedra has been the CEO of the company since 2021.

Kyan Technologies Pte Ltd. is a Delaware corporation that uses AI-based technology to redefine each stage of drug development, from lead optimization through clinical trials. Kyan's flagship platform, optim.ai, employs efficient experiments and relevant, real-time data to power its optimization core. The platform has been validated in more than 40 indications/conditions and has been applied clinically for dosage optimization in solid cancer and HIV. Kyan also works with industry partners to optimize their assets and products. The Singaporean company's mission is to bridge the cancer care gap by advancing revolutionary technologies. The company was founded by Dean Ho, Chih-Ming Ho, and Edward Chow. Hugo Saavedra has been the CEO of the company since 2021.